Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24975582 | 1.00 | RET (0.34) | RETFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL22605599 | 1.00 | RET (0.34) | RETFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL22605320 | 0.85 | EGFR (0.33) | RETFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL24975581 | 0.85 | EGFR (0.33) | RETFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL23961759 | 0.85 | EGFR (0.33) | RETFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL22605321 | 0.84 | PRKD1 (0.33) | RETFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL22605600 | 0.84 | PRKD1 (0.33) | RETFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL19993616 | 0.77 | PRKD1 (0.35) | EGFRFFAR1FFAR4PRKD1KCNH2 | |
| SCHEMBL21163707 | 0.75 | CTSK (0.33) | KCNH2CYP1A2GRM5 | |
| SCHEMBL1814028 | 0.73 | RET (0.42) | RETPDE4DPDE7AKCNH2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332027-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-10710981-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| US-20190210997-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210997-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FGFR1, FGFR4, FGFR3 | RET 37/4885FGFR1 1/4885FGFR4 2/4885 |
| US-10710981-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | FGFR1, FGFR4, FGFR3 | RET 37/4885FGFR1 1/4885FGFR4 2/4885 |
| US-20210332027-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FGFR1, FGFR4, FGFR3 | RET 37/4885FGFR1 1/4885FGFR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.